Merck buzzes Dragonfly for 2nd immunotherapy candidate in $700M pact
- Nov 24, 2021
- 1 min read
Updated: Aug 30, 2022
The dragon is flying high today as Merck hits go on a second immunotherapy candidate from its $700 million pact with Dragonfly Therapeutics. The Big Pharma's buy-in comes just a month after Bristol Myers Squibb licensed its sixth drug from the biotech.
Merck teamed up with Dragonfly for $695 million per program in an October 2018 pact targeting multiple solid tumors. The New Jersey pharma opted into the first TriNKET candidate last November, and the two expanded the collaboration to include infectious diseases and immune disorders on top of the original oncology tie-up.
The partnership revolves around the Massachusetts biotech's TriNKET, or Tri-specific, natural killer (NK) cell engager therapeutics. Essentially, the tech binds to surface proteins expressed on cancer and NK cells.
In disclosing the news Tuesday, Dragonfly's CEO Bill Haney copied and pasted his statement about the collaboration from last year's initial opt-in, noting Merck is a "powerful world leader in drug development" and the biotech is "delighted" the pharma wants to continue with them.
BMS is also happy to keep its partnership with the biotech alive. The Big Pharma signed up for its sixth drug in its own collaboration with Dragonfly last month.
That partnership, originally inked in 2017, has evolved to include hematology malignancies, oncology and neuroinflammation. The TriNKET immunotherapy platform comprises five of the six licensed drugs with the New York Big Pharma.
This collaboration between Merck and Dragonfly is such an exciting milestone for the biopharmaceutical industry, highlighting how innovative partnerships can truly accelerate life-saving breakthroughs. It is fascinating to see the intersection of cutting-edge science and the ethical responsibilities that come with these advancements, which is a topic that often bridges the gap between STEM and social impact. I’ve noticed that many students who follow these industry developments find themselves deep in research regarding the societal implications of biotech, sometimes needing humanities assignment help online to effectively articulate the complex ethical and historical contexts surrounding modern medicine. Thank you for sharing this update—it’s a great reminder of how teamwork can drive the next generation of global health solutions!
This partnership between Merck and Dragonfly is such an exciting development for the biotech industry, especially regarding the potential for innovative immunotherapy treatments! As a student currently diving into the complexities of corporate mergers and pharmaceutical breakthroughs for my degree, I’ve found that keeping up with such fast-paced industry news while managing a full course load can be a total mountain. I actually reached out for some Assignment Help for Leeds Students recently just to get my research on biotech market trends structured properly, which finally gave me the mental space to really analyze the strategic impact of collaborations like this one. Finding a resource like New Assignment Help has been a total lifesaver for my schedule, allowing me to stay updated…
Interesting breakdown of the collaboration here — I liked how clearly the post highlighted the science and business angle behind it. It’s always fascinating to see biotech partnerships like this and how they aim to push innovation forward. I recently read something similar on a review blog https://www.goprogaragedoorrepair.com/, which also discussed how different industries are evolving through smart partnerships. Thanks for sharing this update!
The collaboration between Merck and Dragonfly Therapeutics is such an exciting step forward for the biotech industry. It really shows how meaningful progress happens when innovation meets strong partnerships. Reading this made me think about how collaboration and continuous learning apply in our own lives too. For instance, while working on my personal development assignment, I explored how teamwork and shared vision can drive long-term success — exactly what Merck and Dragonfly are demonstrating here. This partnership reflects how powerful it can be when two forces bring their unique strengths together to make something bigger than themselves. It’s the kind of story that inspires both professionals and students to think beyond limitations. I also appreciate how platforms like New Assignment…
What I kept thinking about while reading was how complex collaborations like this must be behind the scenes, with research, licensing rights, and long development timelines all happening at once. Sometimes discussions about biotech partnerships even spill into unexpected places online—forums where people might be debating academic topics or things like Online Law Assignment UK while talking about intellectual property and how discoveries from smaller biotech firms end up reaching big pharmaceutical companies. It’s interesting how scientific progress often depends on these kinds of partnerships quietly moving forward over years.